ADVENTRX Pharmaceuticals, Inc. — Form 10-Q
Reporting period: Quarter ended September 30, 2012; filed November 5, 2012. The filing identifies the registrant as ADVENTRX Pharmaceuticals, Inc., not Savara Inc.
Business context
ADVENTRX was a development-stage biopharmaceutical company with no current product sales. Its principal focus was ANX-188 (purified poloxamer 188), being developed for complications of sickle cell disease. The company reported that it had not generated significant revenue and had incurred substantial losses since inception.
Key financial metrics
| Metric | Period or date | Value |
|---|---|---|
| Revenue | Three and nine months ended September 30, 2012 | $0 |
| Operating expenses | Three months ended September 30, 2012 | $3.2 million |
| Operating expenses | Nine months ended September 30, 2012 | $11.6 million |
| Net loss | Three months ended September 30, 2012 | $3.2 million; $0.07 per share |
| Net loss | Nine months ended September 30, 2012 | $11.6 million; $0.24 per share |
| Net cash used in operating activities | Nine months ended September 30, 2012 | $10.6 million |
| Cash and cash equivalents | September 30, 2012 | $26.1 million |
| Short-term investments | September 30, 2012 | $13.8 million |
| Total assets | September 30, 2012 | $51.6 million |
| Total liabilities | September 30, 2012 | $5.3 million |
Cash, cash equivalents and short-term investments totaled approximately $39.9 million. Current liabilities were $2.7 million. The balance sheet lists no debt at September 30, 2012. With no revenue, a sales margin is not meaningful.
Changes versus prior comparable periods
- Third-quarter net loss narrowed to $3.2 million from $3.5 million in 2011; loss per share was $0.07 versus $0.13. Weighted-average shares increased to 47.7 million from 26.5 million.
- Nine-month net loss increased to $11.6 million from $10.9 million in 2011, while loss per share improved to $0.24 from $0.43, reflecting a higher weighted-average share count.
- Nine-month R&D expense rose 49% to $6.0 million, mainly due to increased personnel, ANX-188 and ANX-514 manufacturing costs, and ANX-188 clinical consulting. Third-quarter R&D declined 19% to $1.7 million, principally from lower Exelbine manufacturing costs.
- Nine-month SG&A increased 7% to $5.7 million. Operating cash use was $10.6 million, slightly above $10.4 million in 2011. Cash and cash equivalents fell from $43.6 million at year-end 2011; short-term investments increased from $7.1 million.
- No financing cash was received in the first nine months of 2012, compared with $21.0 million of net equity-financing proceeds in the comparable 2011 period.
Outlook, risks and unusual items
- Management expected the September 30 cash and investments to fund the currently planned operating level for at least 12 months, but also stated additional capital would be needed. Future financing might not be available on acceptable terms or at all.
- The company planned to initiate a 388-subject Phase 3 ANX-188 sickle cell study in 2012, targeting full enrollment within 24 months after the first dose. Estimated external study costs were $15–18 million. It also planned a roughly 60-volunteer QT/QTc study in 2013, estimated at about $2 million, plus smaller ANX-188 studies.
- ANX-514 development was limited to animal studies; no clinical studies or significant further manufacturing investment were planned. The company might seek a funding partner or discontinue the program.
- Research and development, regulatory approval, patient recruitment, third-party manufacturing and clinical-study performance present material uncertainties. Management also cited dependence on additional financing and possible dilution from equity or warrant exercises.
- A $0.3 million impairment of ANX-514-related manufacturing equipment was recorded in the second quarter. No impairment of acquired ANX-188 in-process R&D or goodwill was identified in the September 30 annual tests.
- Fair-value changes in contingent consideration associated with the SynthRx acquisition reduced transaction-related expenses by $0.2 million for the nine-month period. The accounting depends on estimates and the company’s share price.
- Management concluded disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the Phase 3 study began as planned, its actual enrollment pace, cost and clinical results.
- Whether cash and investments remained sufficient as development spending progressed, and the timing and terms of any additional financing.
- Actual spending against the stated $15–18 million Phase 3 and approximately $2 million QT/QTc study estimates.
- Potential dilution from outstanding warrants, including 16.5 million warrants reported outstanding at September 30, 2012.
- Progress, partnering prospects or discontinuation decisions for ANX-514 and any expansion of ANX-188 to other indications.